Apart from price action, reasons why I think FebriDx as failed product is its practicality. (obviously my assumptions)
*there was paper published that stated at during ED there were few false/no identification on test FebriDx kit. Lumos responded It by saying something like “there could have been lack of training on how to use it, could be inadequate blood on test kit “ I don’t remember it exactly tho
* on normal cases viral infection are easily identified without test from symptoms like fever and cold , on sever cases, with FebriDx few % inaccuracies compared to lab, I don’t think doctors will opt for it.
* it takes 10 min for it to
It does also sound like you are banking all of Lumos' business on Febridx. It is a primary core product but not their bread and butter business.
yeh maybe, my investment on Lumos was attributed purely because of potential I saw in FebriDx , Lumos was trading at 1c and its value jumped 10-15fold after it received FDA approval for FebriDx on July 3rd. I wonder what its price would be today without the approval.if it wasn’t for Hologic agreement it would be trading at 1-2c, also it is service oriented agreement so I would be expecting much from it .
Facebook going down to 90- it was during a sell off we are in very good period of bio boom, look at DXB
Theranos- Market valued it 9 billion although it was later found it to be fraud . Now look at FebriDx , it’s a FDA approved product yet market is valuing it unfavourably. Does that not tell us something
these are just my 2c . I wish I could be hopeful as you guys but wishful thinking can often turn wrong in these markets
- Forums
- ASX - By Stock
- LDX
- Ann: Lumos Receives US$400k Phase 1 Milestone from Hologic
Ann: Lumos Receives US$400k Phase 1 Milestone from Hologic, page-27
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LDX (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.80M |
Open | High | Low | Value | Volume |
3.7¢ | 3.7¢ | 3.6¢ | $723 | 19.72K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 43596 | 3.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.8¢ | 375607 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 43596 | 0.036 |
2 | 178571 | 0.035 |
2 | 424841 | 0.034 |
3 | 109643 | 0.033 |
2 | 105000 | 0.032 |
Price($) | Vol. | No. |
---|---|---|
0.038 | 375607 | 2 |
0.039 | 30000 | 1 |
0.041 | 239108 | 2 |
0.042 | 676288 | 3 |
0.045 | 100000 | 1 |
Last trade - 15.59pm 23/08/2024 (20 minute delay) ? |
Featured News
LDX (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online